key: cord-1050603-czzb1c7q authors: Bubinski, Michal; Gronowska, Agnieszka; Szykula, Pawel; Kluska, Kamila; Kuleta, Ilona; Ciesielska, Emilia; Picard‐Maureau, Marcus; Lachert, Elzbieta title: Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units date: 2021-03-08 journal: Transfus Med DOI: 10.1111/tme.12763 sha: b9567a1af7dd2bde79cdf225e5f221e66c3ca7af doc_id: 1050603 cord_uid: czzb1c7q OBJECTIVES: Assessment of the impact of pooling five single‐donor plasma (SDP) units to obtain six pathogen‐reduced therapeutic plasma (PTP) units on standardisation and the retention of labile coagulation factors. BACKGROUND: SDP shows a high inter‐donor variability with potential implications for the clinical treatment outcome. Additionally, there is still an existing risk for window‐period transmissions of blood borne pathogens including newly emerging pathogens. METHODS/MATERIALS: Five ABO‐identical SDP units were pooled, treated with the INTERTCEPT™ Blood System (Cerus Corporation, U.S.A.) and split into six PTP units which were frozen and thawed after 30 days. The variability in volume, labile coagulation factor retention and activity was assessed. RESULTS: The variability of volumes between the PTP units was reduced by 46% compared to SDP units. The variability in coagulation factor content between the PTP units was reduced by 63% compared to SDP units. Moderate, but significant losses of coagulation factors (except for vWF) were observed in PTPs compared to SDPs. CONCLUSION: The pooling of five SDP units to obtain six PTP units significantly increases product standardisation with potential implications for safety, economics as well as transfusion‐transmitted pathogen safety, making it an interesting alternative to quarantine SDP (qSDP) and pathogen‐reduced SDP. The total protein profile (including contents of coagulation factors) in individual fresh frozen plasma (FFP) units shows a high variability due to the impact of genetic factors on the human proteome. 1 The majority of infected individuals shows no symptoms, despite positive NAT results. 5-8 SARS-CoV-2 (the virus causing COVID-19) genomic RNA has been detected in blood products from asymptomatic donors. 9 Evidence for transmission by blood transfusion has not been shown yet but cannot be excluded. 10 The current situation shows that the qSDP concept only works for specific pathogens if testing is applied, which is not the case for SARS-CoV-2 as well as potentially newly emerging pathogens in the future. Amotosalen/UVA (AS) pathogen inactivation technology (INTERCEPT™ Blood System, Cerus Corporation), a targeted photochemical reaction irreversibly crosslinking nucleic acids, 11 allows the treatment of pools of five plasma units and splitting into six standardised therapeutic units. 12 The key objectives for this production method are the prevention of transmission of infectious agents and the preservation of the haemostatic capacity as well as the clinical effectiveness. AS-treatment of plasma effectively inactivates a broad spectrum of pathogens, including newly emerging pathogens. 13, 14 In vitro studies revealed a moderate loss of coagulation factors post PI-treatment, with an overall retention meeting the regulatory criteria for therapeutic use. 15, 16 Also, plasma treated with the INTERCEPT Blood System has been analysed in a series of clinical studies including patients with acquired and inherited coagulopathies as well as patients requiring therapeutic plasma exchange. In all these studies, the plasma showed a high level of tolerability and a safety profile comparable to conventional plasma. 17, 18 Our Institute, the Lodz Regional Blood Transfusion Center, is a Polish mid-size blood centre with almost 61.000 whole blood donations in 2018. We produced almost 61.000 plasma units (30% of them for clinical use, 6% of those pathogen-reduced) in 2018. In the current study, we intended to evaluate the impact of pooling five SDP units to obtain six PTP units and AS pathogen inactivation treatment on plasma standardisation and the content of labile coagulation factors as a potential alternative to qSDP and PI-SDP to potentially improve the clinical safety of our plasma products. Samples were collected from the SDPs before pooling, from the pools directly after pooling and mixing (pre-inactivation) and from the PTP units immediately after pathogen inactivation, into Eppendorf ® Safe-Lock microcentrifuge tubes (volume 1.5 ml). Samples were frozen at Comparison of plasma pre and post pathogen-inactivation treatment was performed using the two-sample paired t test. Two-tailed p values of <0.01 are considered statistically significant. Twenty-five SDP units have been collected to generate five pools of five ABO-identical SDP units respectively. Three pools were blood group B, one blood group A and one blood group O. The total volume loss during processing (pooling, pathogen inactivation, splitting) was 5.5 ± 1.9%. However, since six PTP units were produced from originally five SDP units, the total volume reduction per plasma unit was 21.1 ± 3.5%, an additional volume reduction of 15.6% (Table 1) . The difference between the highest and lowest volume was reduced from 40 ml between SDPs to 22 ml between PTPs, a reduction of 46.5%. in PTPs, a reduction of the spectrum of 54.8% (Table 2 ). In total, the distribution of values found for the contents of fibrinogen and labile coagulation factors was reduced 63.4% in PTPs compared to SDPs. The average fibrinogen retention was 78.7% with respect to the concentration (Table 3) . However, the average total fibrinogen content per PTP unit was reduced 37.2 ± 2.5% compared to the SDP units, 24.6% due to processing and 12.6% due to volume reduction by splitting five units into six. The average FVIII retention was 67.8% with respect to the concentration. However, the average total FVIII content per PTP unit was reduced 42.1 ± 11.3% compared to the SDP units, 30.5% due to processing and 11.6% due to volume reduction by splitting five units into six. The average FIX retention was 74.8% with respect to the concentration. The average total FIX content per PTP unit was reduced 40.9 ± 2.6% compared to the SDP units, 29.1% due to processing and 11.8% due to volume reduction by splitting five units into six. Since the average vWF activity was not significantly different pre-and post-treatment (p value 0.014) we also analysed the vWF antigen content, which was also not significantly different (p value 0.377). The average PT was prolonged for 5.2%, the average APTT for 14.5% (Table 3) T A B L E 1 Volumes (ml) of the initially collected single donor plasma units (SDP), the total volume of the SDPs before pooling, the final pathogen-reduced therapeutic plasma units (PTP), the total volume of the originally pooled units post processing (PP) and the total volume loss during processing (pooling, PI-treatment, splitting) as well as the blood groups (BG) of each ABO-identical pool implications for patient clinical outcome. 22 But also, beyond the "standard" factors a standardised product has advantages. The authors of the above-mentioned study furthermore concluded that also the con- The pooling of five SDP units to obtain six PTP units significantly increases plasma standardisation with potential implications for safety of the transfusion recipient, making it an interesting alternative to qSDP and pathogen-reduced SDP, especially in the light of pandemic preparedness. Identification of genetic variants influencing the human plasma proteome The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood What weighs more-low compliance with self-deferral or minor medical procedures? Explaining the high rate of hepatitis C virus window-period donations in Poland Blood transfusion service in Poland in 2018 Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications COVID-19: transmission, prevention, and potential therapeutic opportunities West Nile virus in Europe and safety of blood transfusion Epidemiology of dengue and dengue hemorrhagic fever in a cohort of adults living in Bandung Severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations No evidence of SARS-CoV-2 transfusion-transmission despite RNA detection in blood donors showing symptoms after donation Targeting DNA and RNA in pathogens: mode of action of amotosalen HCl In vitro quality of amotosalen-UVA pathogen-inactivated mini-pool plasma prepared from whole blood stored overnight Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light Component pathogen inactivation: a critical review Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation Hemostatic properties and protein expression profile of therapeutic apheresis plasma treated with amotosalen and ultraviolet A for pathogen inactivation Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen-HCl-UVA (Intercept ) over a 5-year period of extensive delivery Amotosalen-inactivated plasma is as equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function-an in vitro analysis Quarantine versus pathogen-reduced plasma-coagulation factor content and rotational thromboelastometry coagulation Guide to the preparation, use and quality assurance of blood components Is all plasma created equal? A pilot study of the effect of interdonor variability Antibody-mediated transfusionrelated acute lung injury; from discovery to prevention Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units The study was partially supported by Medservice Pro Bis Sp. z o.o. Sp. k.